A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

STATUS

Recruiting
participants needed

36
sponsor

Beijing Cancer Hospital

Send

Updated on 19 February 2024

See if I qualify

cancer

absolute neutrophil count

metastatic urothelial carcinoma

solid tumour

neutrophil count

ejection fraction

carcinoma

systemic chemotherapy

neuropathy

transitional cell carcinoma

adjuvant

oral contraceptives

HER2

cisplatin

Summary

This is an open-label, single-arm, Phase Ib/II investigator-initiated trial of RC48-ADC combined with JS001 to evaluate the safety and pharmacokinetics of subjects with locally advanced or metastatic urothelial cancer

Details

Condition	Transitional cell carcinoma
Age	18-100 years
Treatment	RC48-ADC and JS001
Clinical Study Identifier	NCT04264936
Sponsor	Beijing Cancer Hospital
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Signed informed consent form; Aged 18 years and above; ECOG(Eastern Cooperative'
	b'Oncology Group) performance is 0 or 1; Life expectancy greater than 12 weeks; Patients'
	b'with locally advanced or metastatic malignant urothelial carcinoma which is platinum'
	b'naive and cisplatin ineligible, or progressed after at least one line standard'
	b'ystemic chemotherapy (including progression within 12 months of neo-/adjuvant'
	b'therapy);'
	b'Cisplatinum ineligible patients should meet one of the following criteria:'
	b'Aged 70 years and above, and ECOG performance is 1;'
	b'Serum creatinine >= 1.0xULN or CrCl\\uff1c60ml/min;'
	b'Lose of hearing >= Grade 2;'
	b'Peripheral nerve disorder >= Grade 2 Patients with measurable and appreciable tumor'
	b'lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1);'
	b'Willing to provide primary lesion samples for the purpose of PD-L1 and HER2 tests.'
	b'Adequate organ function as defined by the following criteria:'
	b'absolute neutrophil count(ANC) >= 1.5 x 10^9/L;'
	b'platelets>=100* 10^9/L;'
	b'Total serum creatinine <=1.5*ULN;'
	b'serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=2.5*upper'
	b'limit of normal (ULN), or AST and ALT<=5*ULN if liver function abnormalities are due'
	b'to underlying malignancy; normal serum creatinine ;'
	b'Left ventricular ejection fraction (LVEF) \\uff1e=50%'
	b'Hemoglobin\\uff1e=9g/dl Women of child-bearing potential and men must agree to use adequate'
	b'contraception (e.g., condoms, implants, injectables, combined oral contraceptives,'
	b'ome intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner)'
	b'prior to study entry and during the period of therapy and for 30 days after the last'
	b'dose of study drug;'
Exclusion Criteria
	b'Allergy to RC48-ADC, or JS001, or their components Received anti-cancer therapy'
	b'including chemotherapy, radiotherapy, immunotherapy or other clinical trial treatments'
	b'within 3 weeks of starting study treatment Unresolved toxicities from prior'
	b'anti-cancer therapy, except for alopecia Previously treated with HER2-ADC and/or'
	b'anti-PD-1 or anti-PD-L1 or anti PD-L2 therapies; Underwent major surgery within 4'
	b'weeks of first dose of study drug and not completely recovered; Received vaccine'
	b'within 4 weeks of first dose of study drug Currently active clinically significant'
	b'cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or'
	b'greater than or equal to Class 2 congestive heart failure as defined by the New York'
	b'Heart Association Functional Classification, or history of myocardial infarction'
	b'unstable angina, or acute coronary syndrome within 6 months prior to enrollment in the'
	b'tudy; History of other neoplastic disease within 3 years prior to the study drug,'
	b'with exception of resolved/curable cancers such as basal skin cancer or squamous cell'
	b'kin cancer,.'
	b'Metastasis to CNS(central nervous system) and/or carcinomatous meningitis, with exception'
	b'for the patients who received treatment of metastasis to CNS and/or carcinomatous'
	b'meningitis and had stable disease for at least 3 months, and no evidence of progression'
	b'within 4 weeks of first dose of study treatment. No evidence of new or expanded metastasis,'
	b'and untreated with radiotherapy, surgery or steroid therapy within 4 weeks of first dose of'
	b'tudy treatment.'
	b'History of allogeneic hematopoietic stem cell transplantation or organ transplantation;'
	b'Patients who had received systemic steroid therapy within the last 2 years; Pregnancy or'
	b'lactation; Positive results of HIV testing; Active HBV(hepatitis B virus) or HCV(hepatitis'
	b'C virus) infection Active tuberculosis; Other disorders with clinical significance'
	b"according to the researcher's judgment; Unwilling or unable to participate in all required"
	b'tudy evaluations and procedures'

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer

absolute neutrophil count

metastatic urothelial carcinoma

systemic chemotherapy

neuropathy

transitional cell carcinoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer